Addex H1 FY26 net loss widens 4.29% to CHF 3.46 million; operating loss narrows 15.98% to CHF 1.13 million

By Public Technologies
  • Addex Therapeutics posted a H1 net loss of CHF 3.46 million, widening 4.28% from a year earlier; EPS held at CHF 0.03.
  • Operating loss narrowed 15.98% to CHF 1.13 million, while R&D costs fell 81.07% to CHF 74,000.
  • Cash and equivalents slid 66.67% to CHF 767,000 at June 30.
  • Subsequent to quarter-end, gross proceeds totaled CHF 2.3 million from 52,970,533 shares sold at an average CHF 0.043.
  • Management cited advancing its in-house GABAB cough program and regaining GABAB PAM rights from Indivior; Neurosterix’s NTX-253 Phase 1 readout targeted for Q4 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Addex Therapeutics Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609280100PRIMZONEFULLFEED1001274819) on September 28, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.